Register
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma |
Clinical News
eMediNexus Coverage from: 
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
eMediNexus,  11 June 2019
remove_red_eye 541 Views
#Hematology #Internal Medicine #Oncology

0 Read Comments                

The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!